What you need to know about the forces reshaping our industry.


February 1, 2021

Weekly review: Is it safe to fly? A recent in-flight outbreak shows the risks (and how to reduce them).

Daily Briefing

    What new research reveals about whether vaccines can stop new coronavirus variants, whether the Covid-19 peak is behind us, and more.

    Can vaccines stop the new coronavirus variants? Here's what new research reveals. (Monday, January 25)

    As coronavirus variants continue to emerge, scientists and public health experts have worried that some—especially B.1.351—could evade existing vaccines. Now, new research is shedding light on how effectively vaccines might protect against the new variants.

    Is the Covid-19 peak (finally) behind us? Here's what experts say. (Tuesday, January 26)

    The U.S. daily case rate of the novel coronavirus appears to be slowing, but public health officials say the ongoing race between rolling out Covid-19 vaccines and the quickly circulating new coronavirus variants will ultimately determine whether the nation has finally hit a turning point in its battle against the virus. Here's what we know so far.

    Is it safe to fly? A recent in-flight outbreak shows the risks (and how to reduce them). (Wednesday, January 27)

    Writing for Vox, Abraar Karan, a physician at Brigham and Women's Hospital and Harvard Medical School, describes a recent Covid-19 spreading event on an international flight from Dubai to New Zealand to assess whether flying is safe—and whether that's even the right question to ask.

    What will the coronavirus look like in 10 years? A new study offers a provocative theory. (Thursday, January 28)

    Even after the immediate coronavirus epidemic ends, it's likely the virus will remain endemic in the human population, according to a new study in Science, Apoorva Mandavilli writes for the New York Times. But the virus could look very different than it does today.

    Our take: 4 takeaways on the Novavax, J&J vaccine trial results (Friday, January 29)

    Johnson & Johnson and Novavax separately released preliminary clinical trial data on their Covid-19 vaccine candidates, setting the stage for the companies to seek FDA's authorization for the experimental vaccines. Here's what the data shows—and four things to watch, according to Advisory Board's Brandi Greenberg and Pam Divack.

    Have a Question?


    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.